Top

Published in:

01-11-2018 | Letter to the Editor

Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values

Published in: Annals of Hematology | Issue 11/2018

Excerpt

Dear Editor, …

Aboudola S, Murugesan G, Szpurka H, Ramsingh G, Zhao X, Prescott N, Tubbs RR, Maciejewski JP, Hsi ED (2007) Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation. Am J Surg Pathol 31(2):233–239. https://doi.org/10.1097/01.pas.0000213338.25111.d3 CrossRefPubMed

Meier C, Hoeller S, Bourgau C, Hirschmann P, Schwaller J, Went P, Pileri SA, Reiter A, Dirnhofer S, Tzankov A (2009) Recurrent numerical aberrations of JAK2 and deregulation of the JAK2-STAT cascade in lymphomas. Mod Pathol 22(3):476–487. https://doi.org/10.1038/modpathol.2008.207 CrossRefPubMed

Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J (2017) WHO classification of tumours of haematopoietic and lymphoid tissues, Revised 4th edn. International Agency for Research on Cancer, Lyon

Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, Garcia-Pagan JC, Darwish Murad S, Raffa S, Janssen HL, Gardin C, Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall N, Fenaux P, Valla DC (2008) The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood 111(10):4922–4929. https://doi.org/10.1182/blood-2007-11-125328 CrossRefPubMed

Fujimi A, Kanisawa Y, Minami S, Kamihara Y, Iwasaki S (2014) Focal 18F-FDG uptake in bone marrow on PET/CT in a patient with JAK2 mutation without overt myeloproliferative neoplasm. Int J Hematol 99(1):1–3. https://doi.org/10.1007/s12185-013-1473-y CrossRefPubMed

Mead AJ, Mullally A (2017) Myeloproliferative neoplasm stem cells. Blood 129(12):1607–1616. https://doi.org/10.1182/blood-2016-10-696005 CrossRefPubMedPubMedCentral

Nielsen C, Birgens HS, Nordestgaard BG, Kjaer L, Bojesen SE (2011) The JAK2 V617F somatic mutation, mortality and cancer risk in the general population. Haematologica 96(3):450–453. https://doi.org/10.3324/haematol.2010.033191 CrossRefPubMed

Nielsen C, Bojesen SE, Nordestgaard BG, Kofoed KF, Birgens HS (2014) JAK2V617F somatic mutation in the general population: myeloproliferative neoplasm development and progression rate. Haematologica 99(9):1448–1455. https://doi.org/10.3324/haematol.2014.107631 CrossRefPubMedPubMedCentral

Title: Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values
Publication date: 01-11-2018
Published in: Annals of Hematology / Issue 11/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3363-0

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Localized pain-causing JAK2-V617F-positive myeloproliferation with normal peripheral blood values

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 11/2018

Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)

Severe anemia after trans-catheter arterial chemoembolization—an unusual presentation of hemoglobin Zurich

Drug-to-drug interactions of tyrosine kinase inhibitors in chronic myeloid leukemia patients. Is it a real problem?

Drug-induced liver failure due to rivaroxaban

Comparison of argatroban and fondaparinux for the management of patients with isolated heparin-induced thrombocytopenia

Predictors of clinical responses to hypomethylating agents in acute myeloid leukemia or myelodysplastic syndromes

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page